Dr. Huis graduated in 1973 from the University of La Plata School of Medicine, Argentina. His postgraduate training in Internal Medicine was completed at Ramos Mejia Hospital in Buenos Aires, Argentina. Fellowships in Medical Oncology were completed at the Universidad del Salvador and Chair of Oncology based at the Central Military Hospital, Buenos Aires, Argentina. He completed his oncology fellowship at the Miami Cancer Institute, Florida, USA. He is Head Professor of Oncology and Course Director of Oncology at Maimonides University School of Medicine. Since 1983 he has been Medical Director and Chief of Medical Oncology, Centro Oncologico Buenos Aires (COBA). Since 1996, Dr Hunis has been an Associate Investigator in the ATLAS study, Oxford University, and principal clinical investigator in multicenter studies of Phase II and Phase III breast cancer, lung, melanoma, and cancer-related pain.
Oncology, Breast Cancer; Lung Cancer
Clinical Trials, Clinical Research, Medicine, Pharmaceutical industry, Medical Devices
ALAIN L. FYMAT is a medical-physical scientist and an educator. He is the current President/ CEO and Institute Professor at the International Institute of Medicine & Science with a previous appointment as Executive Vice President/Chief Operating Officer and Professor at the Weil Institute of Critical Care Medicine, California, U.S.A. He was formerly Professor of Radiology, Radiological Sciences, Radiation Oncology, Critical Care Medicine, and Physics at several U.S. and European Universities. Earlier, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs (Office of Research Oversight). At the Loma Linda Veterans Affairs Medical Center, he was Scientific Director of Radiology, Director of the Magnetic Resonance Imaging Center and, for a time, Acting Chair of Radiology. Previously, he was Director of the Division of Biomedical and Biobehavioral Research at the University of California at Los Angeles/Drew University of Medicine and Science. He was also Scientific Advisor to the U.S. National Academy of Sciences, National Research Council, for its postdoctoral programs tenable at the California Institute of Technology and Member of the Advisory Group for Research & Development, North Atlantic Treaty Organization (NATO). He is Health Advisor to the American Heart & Stroke Association, Coachella Valley Division, California. He is a frequent Keynote Speaker and Organizing Committee member at several international scientific/medical conferences. He has lectured extensively in the U.S.A, Canada, Europe, Asia, and Africa. He has published ~ 475 scholarly scientific publications and books. He is also Editor-in-Chief, Honorable Editor or Editor of numerous medical/scientific Journals to which he regularly contributes. He is a member of the New York Academy of Sciences and the European Union Academy of Sciences, a Board member of several institutions, and a reviewer for the prestigious UNESCO Newton Prize, United Kingdom National Commission for UNESCO.
Dr. Fymat's current research interests are focused on neurodegenerative diseases (Alzheimer's, Parkinson's, epilepsy, dementias, and others), oncology (glioblastoma), epigenetics & ecogenetics, and nanomedicine & nanobiotechnology. These are represented in part in his latest books: “From the Heart to the Brain: My collected works in medical science research (2016-2018)”, “Alzhei ...Who? Demystifying the disease and what you can do about it”, “The Odyssey of Humanity's Diseases: Epigenetic and ecogenetic modulations from ancestry through inheritance, environment, culture and behavior” Volumes 1, 2, and 3, Parkin..ss..oo..nn: Elucidating the disease and what you can do about it, and Lyme disease: The great invader, evader, and imitator, and his forthcoming book “Dementia: Fending-off the menacing disease... and what you can do about it”
Dr. Ahed Alkhatib has finished his PhD from Cambell State University in 2011. I am currently working as a clinical researcher at faculty of medicine, Jordan University of Science and technology. Over the time, I have published more than 200 articles in various medical fields including neurosciences, pharmacology, and diabetes. My approaches in research include the involvement of philosophy of science in research which gives looking, and thinking in depth. I have developed several hypotheses in medicine such as the role of white matter in initiating diseases such as diabetes. In microbiology, I have demonstrated that prokaryotic cells and eukaryotic cells are similar in producing cell cycle proteins which can participate in autoimmunity diseases.
Attained D. Pharm in 1991 from SCS College of Pharmacy, Harapanahalli, Karnataka, Department of Drug Control Board of Examining Authority, Bangalore, Bangalore.
UG: B.PHARM 1996 SCS College of Pharmacy, Harapanahalli, Karnataka Gulbarga University, Gulbarga, Karnataka.
PG: M.PHARM 1999 KLE College of Pharmacy, Belgaum, Karnataka Rajiv Gandhi University of Health Science, Karnataka, Bangalore, Karnataka
Ph.D.: In 2011 Acharya Nagarjuna University, Guntur, Andhra Pradesh Acharya Nagarjuna University Guntur, Andhra Pradesh
He is having 20 years of teaching experience in B. Pharm and M. Pharm level and guided 32 M. Pharm students and 03 Ph.D. Scholars in the department under the Rajiv Gandhi University of Health Science, Karnataka, Bangalore. He published 50 research papers in National & International Peer-Reviewed Journals and Presented 41 research papers in various Conferences and Seminars both National and International.
Biochemistry and Molecular Biology, Hormones, Stem Cell, and Nanotechnology.
Radiation medicine, toxicology and cancer
Rabindra Nath Das is a Professor in the Department of Statistics, The University of Burdwan, Burdwan, West Bengal, India. He holds a Ph. D., in Statistics, from The University of Burdwan, India, and Post-Doc from Seoul National University, Seoul, Korea. He has authored more than 125 research articles, and along with a research Monograph entitled- Robust Response Surfaces, Regression, and Positive Data Analyses, published from CRC Press, Taylor & Francis, Chapman & Hall. He wrote research articles on Design of experiments, Regression Analysis, Demography, Quality Engineering, Civil Engineering, Epidemiology, Medical sciences, Environmental, Natural sciences, History etc. His special area of interest is on Design of experiments, Regression analysis, Quality Engineering and Epidemiology. He has received ‘Gopal Kanji Prize 2009’ by The Journal of Applied Statistics and Routledge publications’ for the best article published in volume 36(7), pp. 755-767. He has received certiﬁcate of appreciation for outstanding research by the Editor-In-Chief, Journal of Thyroid Science, given in the Journal Website, for the paper–Vol. 6, No. 2, pp. 1-15. He is acting as Editor, Associate Editor, Executive Editor, Editorial Board Member of more than 135 Journals in Statistics, Physical Sciences, Medical Sciences. He has acted as a Research Professor in 2018-2019 (for six months) & 2019 (for three months) in Data Science for Knowledge Creation Research Center, Statistics Department, Seoul National University, South Korea.
* Theoretical Statistics: 1. Response Surface Design of Experiments (Rotatability & Slope-rotatability); 2. Block Design of Experiments; 3. Regression Analysis; 4. Demography; 5. Quality Engineering; 6. Generalized Linear Models (GLMs) and joint GLMs *Applied Statistics: 7. Quality & reliability improvement experiments; 8. Civil Engineering; 9. Environmental Science; 10. Genetics; 11. Hydrogeology; 12. Bio-statistics; 13. Medical Sciences; 14. History; 15. Epidemiology on Thyroid disease Liver disease, Diabetes, Carcinoma, Cardiovascular disease, etc.
Dr. Arif went to Indian Institute of Toxicological Research (India) for his PhD degree with a major in Biochemical Toxicology. Since 1993, Dr Arif has over 25 years of experience in research & development, academic affairs, academic and general administration as well as quality assurance. He has worked in the University of Kentucky (USA) (1993-2001), King Faisal Specialist Hospital & Research Center (Riyadh, KSA) (2001-2006), and University of Hail (KSA) (2010-2016). He worked as Chairman, Department of Biochemistry in College of Medicine at the University of Hail (2010-2015) and Vice Dean (Basic Sciences) (2015-16) In 2016-2018, he has worked in the Integral University (Lucknow, India) holding simultaneous positions of Dean (R&D), Dean (Academic Affairs) and Pro-Vice-Chancellor. From March 2017 till January 2018, Dr. Arif also worked as the Vice-Chancellor. Dr. Arif has published 95 research articles in peer-reviewed scientific journals, 5 book chapters, and presented 83 scientific abstracts in various conferences/symposia. He also served as an Editorial Board member of various scientific journals including the Chemico-Biological Interactions. He also guest-edited Cancer Letters for a special issue “Technologies in Carcinogenesis and Chemoprevention” in 2013 with Dr. MNV Ravikumar and Dr. V Vadhanam. Besides, he is serving as an active and regular reviewer for many international scientific journals
Biochemical Toxicology, Cancer Chemoprevention, Cancer Informatics and Natural Products Bioactivity.
Dr. Hayashi is professor at Shinshu University Graduate School of Medicine since 2002, and also Section Head, National Hospital Organization Kyoto Medical Center, Japan. He received his Ph.D. from Inst. for Medical Science, University of Tokyo in 1994. He was research training as a resident staff in Virology Division, at National Cancer Center, Tokyo Japan for 3 years until 1994 and joined Whitehead Institute for Biomedical Research (WI)/Mass.Inst.Tech.(M.I.T.) that year. He did postdoctoral training in the laboratory of Dr. Rick A. Young (Membership in the National Academy of Sciences, WI/M.I.T.), and also was a research member of USA Project of AIDS vaccine development (Project Leader: Dr. David Baltimore, Nobel Laureate, Cal.Tech.). After postdoctoral training, he got faculty position Lecture, Mass. General Hospital (MGH)/Harvard Medical School (HMS) in 1997. He has been studying the antigen presentation system by MHC class I with LMP2-deficient mice, under the cooperation of Dr. Susumu Tonegawa (Nobel Laureate, M.I.T.). He identifies diagnostic biomarkers, LMP2, Cyclin B1 and Cyclin E, for malignant tumor, i.e. uterine leiomyosarcoma, and BRCA1 and S100A4 for ovarian carcinoma.
Molecular approach of tumorigenesis of uterine leiomyosarcoma and ovarian cancer.
Metastatic breast cancer, Iron deficiency anaemia, Ovarian cancer, Stomach Cancers
He has obtained his Doctor of Philosophy (Ph.D.) for his work titled “Salivary and serum metabolomics in oral leukoplakia and oral squamous cell carcinoma” and his field of interest includes oral pre-cancer, oral cancer, salivary diagnostics, metabolomics, and oxidative stress. He has several scientific publications and actively contributes as a peer reviewer to numerous journals. He is an active member of the editorial board of several journals of repute. Dr. Gokul Sridharan has undergone training and is a qualified diploma holder in medical law and ethics and is also certified in tobacco cessation and control.
Oncology, Breast Cancer.
Clinical Oncolgy and Radiotherapy.
Having graduated from University of Punjab, Lahore in October 2009,he joined Shifa international Hospital Islamabad (JCI accredited) as hospital pharmacist after 2 years selected in Shaukat Khanum cancer hospital and got 3 promotions in a timespan of less than 6 years. Currently working as head of clinical pharmacy services at Skmch .His passion for studies embraced him to get MBA and M.Phil. Degree in 2012 and 2016 respectively. Actively involved in research and development, with 4 publications and participated in various clinical phase 3 trials, including the current Cansino trial for Covid Vaccines by Chinese government.
Medical treatment of Haematological malignancies and Sarcomas
I got my MD/Ph.D. degree from West China University of Medical Sciences, and did my postdoctoral training at Medical Schools of Oxford University UK as well as Vanderbilt University USA. I worked as an R&D scientist at Eli Lilly Pharmaceutical Company for 6 years, a senior research fellow at Harvard Medical School for 3 years, and a senior scientist at IU Simon Cancer Center for 2 years. I was also working as the director of the new drug discovery center at Yiling Pharmaceutical for 5 years. I have 2 innovative drug patents and 42 biomedical publications.
Treatment-related to bio-medical sciences of major diseases.
Tissue Culture, Cancer Multidrug Resistance, Anticancer Drug Development, Cancer Biology, and Cancer Metabolomics.
Interested in all fields of Oncology and Radiation therapy
Dr. Goel obtained DNB Radiotherapy & Completed training at Rajiv Gandhi Cancer Institute & Research Centre between 08/2008 - 08/2011 & passed final practical exams in December 2014 session at Tata Memorial Hospital, Mumbai, India. Completed MBBS from Baroda Medical College, Maharaja Sayajirao University, Baroda, Gujarat, 1997- 2003. Also completed Fellowship in High Precision Radiotherapy from Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India (02/2014-08/2014), Fellowship in Stereotaxy, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India (08/2014-02/2015).
Radiation Treatment Planning, Mold Room Planning, Quality Assurance of state of the art radiotherapy equipment - LINAC, HDR and LDR Brachytherapy, 3DCRT, IGRT, IMRT, SBRT, SRS